[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100524249":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":13,"centralContacts":21,"locations":27,"responsibleParty":42,"collaborators":45,"id":49,"slug":50,"hasResults":51,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":55,"eligibilityCriteria":56,"healthyVolunteers":51,"sex":57,"minAge":58,"maxAge":59,"enrollmentInfo":60,"targetDuration":7,"studyType":63,"phases":7,"briefSummary":64,"conditions":65,"keywords":67,"overallStatus":30,"whyStopped":7,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":80},{"fullName":5,"class":6},"Mayo Clinic","OTHER",null,[9],{"type":10,"name":11,"description":12,"armGroupLabels":7,"otherNames":7},"DEVICE","Rectal Artery Embolization","Subjects will undergo planned rectal artery embolization (RAE) in Vascular and Interventional Radiology per standard clinical protocol.",[14,18],{"name":15,"affiliation":16,"role":17},"Scott Thompson, MD, PhD","Mayo Clinic, Vascular and Interventional Radiology","PRINCIPAL_INVESTIGATOR",{"name":19,"affiliation":20,"role":17},"Scott R Kelley, MD","Mayo Clinic, Colon and Rectal Surgery",[22],{"name":23,"role":24,"phone":25,"phoneExt":7,"email":26},"Desirae Howe-Clayton","CONTACT","507-255-0111","Howe.Desirae@mayo.edu",[28],{"facility":29,"status":30,"city":31,"state":32,"zip":33,"country":34,"countryCode":35,"cosmosGeoPoint":36,"geoPoint":41,"contacts":7},"Mayo Clinic Minnesota","RECRUITING","Rochester","Minnesota","55905","United States","US",{"type":37,"coordinates":38},"Point",[39,40],-92.4699,44.02163,{"lat":40,"lon":39},{"type":17,"investigatorFullName":43,"investigatorTitle":44,"investigatorAffiliation":5,"oldNameTitle":7,"oldOrganization":7},"Scott M. Thompson","Principal Investigator",[46],{"name":47,"class":48},"Terumo Corporation","INDUSTRY","100524249","outcomes-and-quality-of-life-following-rectal-artery-embolization-for-bleeding-internal-hemorrhoids-100524249",false,"NCT06106269","Outcomes and Quality of Life Following Rectal Artery Embolization for Bleeding Internal Hemorrhoids","Hemorrhoidal Embolization Trial-1 (HEMBO-1)","HEMBO-1","Inclusion Criteria:\n\n* Grade II or III hemorrhoidal disease as determined by a board-certified colorectal surgeon.\n* Persistent or recurrent symptoms following hygiene and dietary measures or medication.\n* Bleeding predominant ± pain symptoms.\n* Undergoing planned rectal artery embolization (RAE) per standard clinical care.\n* Male or female with age greater than 18 years, with the capacity and willingness to provide a written informed consent.\n* Negative pregnancy test (if applicable).\n\nExclusion Criteria:\n\n* Prior hemorrhoid surgery.\n* Grade IV hemorrhoidal disease.\n* Acute hemorrhoid complications.\n* Chronic anal or perianal fissures.\n* History of colorectal surgery or pelvic radiation.\n* Inflammatory bowel disease.\n* Portal hypertension or mesenteric venous congestion\u002Focclusion.\n* Inferior mesenteric artery (IMA) or internal iliac artery (IIA) stenosis or occlusion.\n* Contraindication to iodinated contrast.\n* Pregnant and\u002For breast-feeding subjects. A negative pregnancy test within 48 hours of the procedure per clinical care.","ALL","18 Years","90 Years",{"count":61,"type":62},20,"ESTIMATED","OBSERVATIONAL","This study will assess how effective and safe rectal artery embolization works to treat symptomatic bleeding predominant internal hemorrhoids.",[66],"Internal Hemorrhoid",[68,69,70],"Bleeding","Anemia","Hemorrhoid","2026-06-15",{"date":73,"type":74},"2026-06-17","ACTUAL",{"date":76,"type":74},"2024-06-07",{"date":78,"type":62},"2026-12",{"name":5,"class":6},1]